120 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
10 Jun 24
Other Events
6:05am
(25 & 50 mg Cohorts) Goal: Further characterize PK/PD and assess safety to inform long-term dose and dose regimen Treatment Schedule - nomlabofusp (CTI … Eligibility Criteria Previous participation in Phase 1 or Phase 2 trials Key Study Objectives Safety and tolerability Long-term PK Dose escalation to 50
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
30 May 24
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich’s Ataxia
4:08pm
label extension (OLE) study to assess the long-term safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues in patients
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
further characterization of frataxin PD at the 25 mg dose. The OLE study is evaluating the long-term safety as well as frataxin levels following daily … 50% of the average healthy volunteer level.
The long-term safety and tolerability, pharmacokinetics, and frataxin levels in peripheral tissues
8-K
EX-99.2
LRMR
Larimar Therapeutics Inc
20 May 24
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich’s Ataxia
4:08pm
of Ambulation
Completed Ph 2 Dose Exploration Study (25 & 50 mg Cohorts) Goal: Further characterize PK/PD and assess safety to inform long-term dose … and tolerability Long-term PK Dose escalation to 50 mg planned following further characterization of FXN pharmacodynamics at 25 mg dose Tissue FXN
8-K
EX-99.1
3twgrpdb8no1y0u
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
8-K
EX-99.2
6x31h74idtfo
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
PRE 14A
jhk ywq7hq7stjl
12 Apr 24
Preliminary proxy
6:06am
8-K
EX-99.1
mue8vqydq6t wmm33j
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
EX-99.1
y3pi21 1g4
11 Mar 24
Other Events
4:09pm
8-K
EX-99.2
q65lcpn r8rvkkil1
11 Mar 24
Other Events
4:09pm
8-K
EX-99.3
p7qy9bns9hnbes
11 Mar 24
Other Events
4:09pm
8-K
EX-1.1
vxmlepa
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
ir6tsji
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
scrhnchk
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
3viabuf9
12 Feb 24
Results of Operations and Financial Condition
7:03am